Cover Image
Market Research Report

Opioid-Induced Bowel Dysfunction (OBD or OIBD) - Pipeline Review, H2 2016

Published by Global Markets Direct Product code 410979
Published Content info 31 Pages
Immediate Delivery Available
Price
Back to Top
Opioid-Induced Bowel Dysfunction (OBD or OIBD) - Pipeline Review, H2 2016
Published: December 30, 2016 Content info: 31 Pages
Description

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Opioid-Induced Bowel Dysfunction - Pipeline Review, H2 2016, provides an overview of the Opioid-Induced Bowel Dysfunction (Toxicology) pipeline landscape.

Opioid-induced bowel dysfunction (OIBD) is refers to a collection of primarily gastrointestinal motility disorders induced by opioids. OIBD is commonly associated with the chronic use of opioid analgesics. Symptoms include constipation, anorexia, nausea and vomiting, gastro-oesophageal reflux, delayed digestion, abdominal pain, flatulence, bloating, hard stool, straining during bowel movement and incomplete evacuation. Treatment includes laxatives, stool softeners, osmotic agents and opioid antagonist.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Opioid-Induced Bowel Dysfunction - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Opioid-Induced Bowel Dysfunction (Toxicology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Opioid-Induced Bowel Dysfunction (Toxicology) pipeline guide also reviews of key players involved in therapeutic development for Opioid-Induced Bowel Dysfunction (OBD or OIBD) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Preclinical and Discovery stages are 3 and 3 respectively.

Opioid-Induced Bowel Dysfunction (Toxicology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Opioid-Induced Bowel Dysfunction (Toxicology).
  • The pipeline guide reviews pipeline therapeutics for Opioid-Induced Bowel Dysfunction (Toxicology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Opioid-Induced Bowel Dysfunction (Toxicology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Opioid-Induced Bowel Dysfunction (Toxicology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Opioid-Induced Bowel Dysfunction (Toxicology)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Opioid-Induced Bowel Dysfunction (Toxicology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Opioid-Induced Bowel Dysfunction (Toxicology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Product Code: GMDHC8892IDB

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Opioid-Induced Bowel Dysfunction (OBD or OIBD) Overview
  • Therapeutics Development
    • Pipeline Products for Opioid-Induced Bowel Dysfunction (OBD or OIBD) - Overview
  • Opioid-Induced Bowel Dysfunction (OBD or OIBD) - Therapeutics under Development by Companies
  • Opioid-Induced Bowel Dysfunction (OBD or OIBD) - Pipeline Products Glance
    • Early Stage Products
  • Opioid-Induced Bowel Dysfunction (OBD or OIBD) - Products under Development by Companies
  • Opioid-Induced Bowel Dysfunction (OBD or OIBD) - Companies Involved in Therapeutics Development
    • ChironWells GmbH
    • Orphomed Inc
    • RaQualia Pharma Inc
    • Vitality Biopharma Inc
  • Opioid-Induced Bowel Dysfunction (OBD or OIBD) - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • ORP-102 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ORP-106 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RQ-00433412 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Antagonize Mu Opioid Receptor for Gastrointestinal Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VB-100 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VB-210 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Opioid-Induced Bowel Dysfunction (OBD or OIBD) - Dormant Projects
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Opioid-Induced Bowel Dysfunction (OBD or OIBD), H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Opioid-Induced Bowel Dysfunction (OBD or OIBD) - Pipeline by ChironWells GmbH, H2 2016
  • Opioid-Induced Bowel Dysfunction (OBD or OIBD) - Pipeline by Orphomed Inc, H2 2016
  • Opioid-Induced Bowel Dysfunction (OBD or OIBD) - Pipeline by RaQualia Pharma Inc, H2 2016
  • Opioid-Induced Bowel Dysfunction (OBD or OIBD) - Pipeline by Vitality Biopharma Inc, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Opioid-Induced Bowel Dysfunction (OBD or OIBD) - Dormant Projects, H2 2016

List of Figures

  • Number of Products under Development for Opioid-Induced Bowel Dysfunction (OBD or OIBD), H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Targets, H2 2016
  • Number of Products by Stage and Targets, H2 2016
  • Number of Products by Mechanism of Actions, H2 2016
  • Number of Products by Stage and Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top